Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't submit commentary to this message board with the intention of making friends or enemies. I just call it as I see it given the information available for review. First of all, it has been three years since the overall markets have been this unkind to small-cap biotechs, small-cap medical device companies, and small-cap pharma in general. The flight to quality and the flight to dividends continue, and no one knows when this burden will ease. The company with which Medizone has chosen to partner for manufacturing purposes has challenges of its own in this hostile environment. A change in top-line management, an acquisition, a corporate restructuring, and a refinancing of the company's line of credit facility have occurred within a few months of each other. Revenues for 2011 are way down from 2010, and gross profit margins are really suffering. The silver lining in the SMTC 10Q, however, is the robust revenue and profit projection for 2012, and these numbers were published long before the Medizone deal was announced. The ZF Array acquisition will cost cash and debt but should bring immediate help via the 27 million in revenues it is currently producing. Do I think this is a good deal for Medizone? I don't know. SMTC currently is capable of producing over 200 million in revenue but also is capable of producing tax-loss carryforwards. The company is not awash in cash, and there is little room for error and even less room for the loss of a customer. It's all in the 10Q. Have a look. I guess I'm scratching my head as to whether or not Medizone could have found a more financially secure partner in Canada. I do have one question: Under what area of "Product Expertise" for SMTC should Asepticsure be categorized?
It's intesting that SMTX stock has risen about 75% in the last three weeks. Prior to this deal, the company announced just one other deal on Nov. 17 having to do with "next generation" WiFi. There has been a little insider buying. The CEO added 20,000 shares to his holdings in early September.
This market, in general, produces anxiety in many people. Europe is trying very hard to avoid the derivatives calamities that we endured, in 2007-08, that brought down the Big Eight. The market's current definition of "long term" is tomorrow afternoon....no matter what day of the week it is. We are in a reactionary trading environment and not a true investing environment. That being said, the popular averages are down compared to earlier in the year, and tax-loss selling is in full swing. Medizone stock probably is being affected by selling from some shareholders who bought it in the $.40 area several months ago. That situation will end 12-31-11. So more patience is required until a series of patents get issued and we find out, in much greater detail, the extent of the background work for product development and partnering that has been done....as described in basic generalities in the 10Q. The bottom line remains that we need a prototype finished product that can produce independent verificiation of test results whether it pertains to HAIs or bedbugs. And we need it pretty soon. Nothing else really matters without it.
Well, Judy..........it's a waiting game. A few people on this board have offered insight into when the company might obtain a review from a patent office somewhere in the world. If their calculations are accurate, we could be looking at a matter of a few weeks. The big challenge comes if/when the company is issued patents. Then pages 20 and 21 of the 10Q will come into play, and we'll see how much promotional background work actually got done. As of today, however, we remain FIME + 3 (months) with no visible product.
A lot of hope remains on this message board. I certainly hope patents and products are in your futures.
Just in case Medizone's promotional gurus missed the Forbes article, I took the liberty of sending an e-mail to the author of the article, Christina Aragon. She has a Harvard and Wall Street background and currently is involved with the company: Rent.com I told her that Medizone is awaiting patents on an ozone/hydrogen peroxide propulsion system that decontaminates hospitals and kills bedbugs. Maybe she'll at least have a look at the website.
Even the Rotary International magazine October 2011 issue had an article on bedbugs. Rotary is within 1000 cases of knocking out polio. Maybe it should be allowed to tackle bedbugs.
The activity on this board seems pretty quiet compared to many of the available boards. I suppose that's because there is a lot more potential product reality and a lot less hype with BPAX than many other small companies, medical and otherwise. Is this just a waiting game now for safety results for Libigel?
Whether this board is silent or vocal, large blocks of stock remain on the sell side of future transactions the way it looks right now. Whether this board is silent or vocal, we remain two months past FIME without a product. Could I possibly have a few of my questions answered with an e-mail to our new IR guru? I certainly hope not. Frankly, I don't want to know anything that the rest of you don't know. I want us all to learn about it together. That's they way it's supposed to be. Thousands of companies, over the years, have come and gone via the pink sheet and bulletin board markets. The vast majority of them never make it for a variety of reasons. Medizone has an opportunity to be a shining star amid a universe of floating debris. Some of you have posed complex and difficult questions to your new IR person. I would hope that the calculated answers to these privately asked questions are deemed important enough to be shared with the entire Medizone shareholder universe.
Efficacy numbers are exceeding expectations and on-going safety trials do NOT require modification. Hmmmm. Activity is quiet, at best. Is the safety trial the point of concern here?
Cjboro...nothing I would like better than to see MZEI shareholders finance the birth of an industry that could spawn into several huge sub-industries, improve the health of millions of people, and then be financially rewarded themselves for taking the risks inherent to that part of the OTC market known as the Bulletin Board.
I sleep very well with my investments, Phrantic, and have been in the markets for 30 years. My investment in Medizone won't break my bank if it doesn't work out. Rarely do I invest in a penny stock situation like this one. Having known a bit of this company's history for so long, however, I was prompted to take a third look upon the discovery of AscepticSure. Knowing that other large companies with huge resource bases believe that they are viable competition and already are out in the marketplace trying to prove themselves right also prompts me to remark about potential time constraints with which the company has to deal. Here's another hypothetical situation. Patents are pending and could be granted in the next few months. Let's say some major country's patent office requested an in-person demonstation of the apparatus before granting a patent. Could it be done?
That's the way Disney World trips worked at my house too, Judy. You knew who was taking you, when you were leaving, how long it would take to get there, and what to expect upon arrival. All the rides were up and working, weren't they. Your family wouldn't have made the trip under any other circumstances. I reiterate that, if this company was a P&G, we wouldn't be having 99% of these discussions. To BenK......my hypothetical situation on which you commented actually is very real but, in theory, will always remain hypothetical, won't it. Product development updates, anyone?
Let's see.....Bruce...Bruce...hmmm...Bruce...Oh Yeah....now I remember: He's the person given the internal Investor Relations position whose first act in that capacity was an attempt to intimidate and threaten this message board. Nope....can't say that I have had any use for him yet.
Not at all, Benk. First of all, I was not aware, until your post, that issues really existed. Second of all, it is not the place of a normal shareholder to offer assistance unless asked. Thirdly, I offered a hypothetical situation as an example that some of the people making up the 3000+ shareholders might have some connections that could help in various areas. Lastly, I would hope that a formal company meeting would give management a chance to ask for help, if needed, and for shareholders to offer help, if able.
Interesting revelations, BenK. So management has been venting to you, in recent months, about its frustrations with product development, test results, etc. Medizone is not P&G with a few hundred thousand shareholders, many of whom own the stock primarily for its dividends. Three thousand+ shareholders are excited about this little company's prospects for state-of-the-art products and its uncanny ability to save and improve lives once these products are introduced. Three thousand+ shareholders care about this company, and many of them would be honored to help it, either directly or indirectly, reach its goals. For example: one of these shareholders might have a best friend with 35 years experience as an electrical engineer (with patents under his belt) who is an expert dealing with computerized circuit boards for the heating and air conditioning industry. This person certainly knows about propellents and propulsion and also deals with his city's largest refuse company.....that deploys ozone. A shareholder meeting could be used to brainstorm ideas and establish new contacts that might help Medizone get a viable product to market sooner rather than much later. We are helpless, however, until the issues are shared with us. This type of helplessness breeds restlessness.
I saw, in Ohio and Kentucky last week, billboard ads for pest control companies offering bed-bug extermination.
Okay....now we're starting to get some better dialogue about substance.....even from some of our historical cheerleaders. We need to realize that, one way or another, this is Medizone's last shot at accomplishing something monumental. Twenty five years of nothing happening is either going to change dramatically or continue into obvious oblivion. Every one of you would love to see a product come along, like AsepticSure, that would give you the golden opportunity to help mankind and make a few bucks at the same time. Your hearts are in the right place yet many of you keep your blinders on as to how all of this miracle work is going to be created. It's time for a serious shareholder meeting instead of a pre-screened audio question and answer session. I guess I have been in the business world too long. Pardon my obsession with FIME. I'm glad I chose, at the last minute, to go to Quantico instead.....yet I would have enjoyed a few debates with Gelati.
Yep....It's time for a serious shareholder meeting. I will gladly, just as in the past, fly from Florida to California to find out where all of us stand. Then again, maybe we should have this meeting either at Purdue or at the actual hospital complex in Canada. I am sure that the officers of these two institutions would enjoy the publicity of having an "annual" meeting held on their premises.....especially with breaking technology as important as AsepticSure. What say all of you?
Eli.....Your post 21792 contains some tell-tale references that, like it or not, we have seen happen on this board from time to time. Lately, however, this board also seems to be "coming to grips" better with the issues facing the company and its shareholders. We can sit here and talk about product and its potential applications until we're all blue in the face. The reality "checks", however, are letting us know that the whole idea of "moving forward" from here is a huge hurdle. No one can expect current market conditions to look favorably upon a penny stock without a tangible product and filmed demonstation to show. Today's market is not a speculator's market. We're seeing a "flight to quality" every day. So....where is the product that should have been physically introduced at FIME in August?
Every member on this board, as I have stated before, have bought products where the patents were pending. The competition, even though it can't seem to get the formula right, is out there trying to make things happen. What we're all hoping for is that Medizone never has to legally defend a patent that it obtains. Yes, I would love to see sales every week right now. I would settle, however, for knowing that target markets in target industries are being identified and contacted and that a game plan is close to being in place. That ain't happening. The chance is quite high that the company, if it is able to sell itself to the proverbial Fortune 500 company, won't have an actual clue as to what it is worth. That's not fair to you, mtsr, or the rest of us.
We're rapidly moving toward the two month mark after the FIME show. The Geneva conference and FIME created enough hype to maintain the .20 stock price. Those events, however, are well behind us now. What's next? The longer the time period without news (and I mean meaningful news) at this point, we will have to
endure a trickling down stock price. MZEI is no different than any other penny stock in this regard. Prices are news driven. Patent acceptance and independent verification of the science will be the most significant news for which this little company could hope. The Canadian patent allowance situation turned out to be a non-event for the stock price. It's great to see the articles transmitted by members of this board that talk about yet more applications for the science. Our on-going problem, as we all know now, is that management has to address these potential industry applications with gusto. The patent allowance announcement obviously is not bold enough to cause management to spring into action with a marketing plan.
Does anyone know if management is intending to attend the Purdue bed-bug conference in January in West Lafayette? Purdue really is the first opportunity for the company to receive a dose of independent verification of the science. Historical credibilty issues is one reason why this company's stock continues to languish at .17. The hype is over. Jerry McGuire would be saying "Show me the independent test results".
Well.....no one bothered to answer my question on how to get the company from point A to point B. So I will follow up with a few more logical questions: Who does actually hold the patents? Where is the independent verification of the testing? When can a video demonstration of the equipment become available with several of the announced potential applications? Too many claims are being made "in-house" without supporting data from test facilities. Don't you think a U.S. patent office would be most interested in this information?
Backseat drivers are going to be created in any environment where management is as quiet as this management seems to be. I do not refer to announcements concerning the science. I refer to the ability/inabilty to convert this company from a research facility with zero revenues to a thriving metropolis of commerce. If someone on this board has the wherewithall to explain this procedure to me, I and, I would hope, the rest of us, would be most interested
Medizone, like other stocks in its price category, will not be on the radar of market traders. So the ompany can avoid the daily volatility that we see with the NYSE Composite and the NASDAQ. One area where we need to be concerned, however, is the focus on the global economy itself. European banks seem to be on the verge of causing similar problems experienced in our own financial system three years ago. Should we undergo another contraction in the global money supply that would cause a sell-off in the stock market solely for the reason of raising cash, then we will have to rethink future valuations for Medizone and every other low priced stock with a potential blockbuster technology. Example: Go back five years. Would a corporate giant have paid more for a technology like Medizone's in 2006 before everything hit the fan in late 2007? You betcha. Determining a real value for the shareholder becomes paramount at this juncture given the difficulties in the world economy.
Great stuff, Judy. NBC4 and all the parties listed in the article should receive information about Medizone. Central Ohio did its bedbug conference right.....in the summer. Purdue plans to hold one in West Lafayette in the middle of January? Brrrrr!
Every article recently sent to this board lists and/or quotes the major players who become the bases for the articles. Every one of these important people in this area of healthcare should be aware of Medizone and what AsepticSure can do. I guess, as shareholders, we might have to take a few of the bulls by the proverbial horns and contact them ourselves. I never miss a chance, if I am around a medical person, to ask questions relating to HAIs and inform said person that a possible antidote exists. Unfortunately, no one to whom I have ever spoken has heard about Medizone. I hope all of you sending informative articles to this board also copy management on them.
My earliest posts dealt with questions concerning the ability/inability of a company with this type of resource base to stand alone long term. Two years of identifying the size and shape of potential markets have been lost because the company did not hire an outside firm to begin gathering information. If the firm cannot go it alone, then it has an obligation to shareholders to bring top dollar for the shares. Should the company be so fortunate that the U.S. Patent Office grants use patents for the equipment and the mixture, the ability to sell the company for top dollar will be based on demand for the products in a variety of markets. How will that demand be determined at this point.....and when will those determinations begin? Many of you on this board have been loyal servants for a long time, and I don't want to see any of you disappointed. Your hearts, obviously, have been in the right place. This board also has a few potential "flippers", and that remark is not a criticism. All boards supporting low priced stocks have some short term traders as part of their dialogue base. We do have to ask ourselves a couple of questions at this point: What would change tomorrow if the patents were granted today? How long would it take to fill an order of 100 units? Given what we know/don't know about potential markets, how would we, as shareholders, be able to determine a fair price for the company's shares upon the sale of the company? Ladies and gentlemen, I believe the company needs to start addressing these areas now before it really gets too late.
What, where, and to whom By Whom
We're almost a month past FIME now. The stock languishes at .20 with extremely low volume. The Eversull Group continues to be the shareholders' scapegoat for their frustrations. Competition, we find out, does exist, and its science is being marketed. One thing we should observe from the competition is its willingness to take a few chances. No one has patented the mixture. Yet the competition understands the potential importance of the product and procedure or it would not have bothered to make its first sales call.
Thanks for the clarification. Looking at the video from our computers, it looked like a ghost-room in there. When the person running the camera zoomed out to give us a peek at the slides to the doctor's left, I couldn't see the tops of anyone's heads seated near the podium. Do we have an actual head count?
Well, I received a lot of viable information watching the video, but I watched the video twice today to make sure I didn't miss something......like an audience. How many people were supposed to have been there besides the corporate officers standing in the back?
Dr. Zoutman's responsibility now lies with four hospitals. Sure...we can hope his four hospitals buy up a bunch of Medizone product. Can we expect Dr. Zoutman to help market Medizone's product outside of those four hospitals? He claims to still be active with patients. Where will he find the time, and why would Quinte's BOD allow him independent outside interests? Did anyone find it a bit of a dismay that Medizone was not mentioned once in Dr. Zoutman's press release? Until told otherwise with conviction, we have to surmise that he has bailed on Medizone because important background work continues to not get done. Whatisvalue's most recent post has hit a few nails on the head......again. The noise from those nails, however, usually fall on deaf ears. Management supporters soon will be circling the wagons, as always. My ultimate fear, as noted in my first couple of posts, is that you all will be discussing the same aspects of this company one-two years from now that you are discussing now. Should patents be granted today, what really would change tomorrow? A sale of the company for mere pennies of potential value is all we could expect today under the current circumstances. "Pie in the sky" doesn't cut it anymore. What needs to be done? Anybody?
Everyone should realize that management should have the NASD and SEC booklets on insider information and insider trading sitting right on the desk in plain view. No one should expect management to relay sensitive information regarding the company to this or any other message board, or anyone on it, without first posting it on the website, delivering it through a publicly announced conference call, or issuing it through a press release. That could be one reason the request for another conference call is being made. 1. What really happened at FIME? 2. What is really happening at Purdue? What is happening, to management's best knowledge, at the patent office? What are management's thoughts about marketing and manufacturing going forward now that an order for product was requested sight unseen at FIME?
What an interesting historical analogy, Smeatz! May I be permitted a simple tweak?
"Young adult goes for job interview = FIME"
Young adult sends a resume' to the jobs fair but doesn't attend in person.
Everyone needs to start focusing on the point that the company is not ready. The upcoming bed bug conference is a prime example. Maybe FIME also should have been skipped. Having spent almost 40 years in the private sector, I could not imagine my logo at an event the size of FIME without my main product on display for demonstration.
Long term shareholders are the most antsy because they have held on the longest through many years of inaction. Some of them are still asking themselves what, if anything, has changed much.
Heystan has seen it all....having been employed to do work for the firm as far back as 1987. I first read about the company in an old ultra right wing newspaper, called The Spotlight, that I found on an airline, also back in 1987. The article stated that Medizone had been cleared for clinical trials recycling blood through its ozone machines. That statement was a huge untruth. Unfortunately, the company never got that far. The FDA and ozone do not have a positive relationship going backward. My memory is a bit shaky, but I seem to recall reading that the physical handling of ozone back in the 1930s resulted in the deaths of technicians. The FDA actually publicly dissed the importance of ozone as recently as the mid-1970s. Heystan....It would be great for you to fill us all in on more of the early history. The company had some successes in early animal trials with pigs and monkees but always managed to find a way to be unable to move forward. The late CEO Watrous might have been able to get some things done. Heystan certainly could deliver an interesting historical workshop for us.
The company might be able to go it alone with proper advanced planning on several fronts pertaining to marketing and production. Identifying those markets based on the granting of use patents, however, is a long trial and error process that probably should have begun two years ago. The company is behind the proverbial 8 ball and may have no choice but to sell out early. This scenario, unfortunately, happens with a lot of penny stock companies in the medical field. Most of them never bring a product to market because of shortcomings in the science. The remainder of the companies have scientific savvy but no marketing savvy and thus quietly go away or are sold for pennies compared to actual worth because of the ongoing disconnect between science and potential markets. Big companies know the problem and exploit it whenever they see the advantage. General Electric and Imatron would be an example. Johnson and Johnson and Scios would be another example in the last decade. Sometimes there's just not enough money to see it through inspite of advanced planning and expert marketing.
Current market conditions are not going to favor speculative penny stocks when the world is fleeing to the supposed safety and quality of a ten year U.S. treasury note yielding 2%. Medizone's stock is way under the market radar even when there is no panic selling of the stock market in motion. Waiting for patents to be approved before a business plan is developed, however, will result in more delays even in the best market conditions. Current management should be hiring this entire message board as its marketing guru. Right now, it's the only marketing arm the company knows. Developing a business plan fosters name recognition to thousands of potential investors. Every hospital and hotel in this country already should know that Medizone exists. What is it going to take to make that happen?
I find it interesting that The Eversull Group has become a scapegoat. I am not defending anything, however, that his Group has done or failed to do. I haven't been sure what to expect from the Group given what the Group was handed with which to work. We surely don't know enough at this point. So...I guess my question is: Is the Eversull Group responsible for the current information, trading and price malaise or are these phenomena more directly related to Medizone's shortcomings at FIME? Management could be quite pleased that fingers are being pointed in a different direction right now. Public relations groups always can be replaced when their current contracts run out.